The bioelectronic medicine developer has been snapped up by Astellas, two years after the latter took part in its series A round.

Q&A with Rob Coppedge, chief executive, EHV

The short bowel syndrome therapy developer has added $110m to the $35m with which it emerged from stealth in January.

Taiho Ventures and SR One co-led a series A round that will fund the early clinical progress of Dren's cancer and protein-depletion drug candidates.

Evotec and Boehringer Ingelheim Venture Fund returned in a $25.9m round for the autoimmune disease drug developer having first invested three years ago.

Topas Therapeutics, which is exploiting University of Hamburg research, has pocketed $26m in its series B round.

The round was led by $8m from Leaps by Bayer and increased the microbiome skin treatment developer's total funding to $34m.

Eli Lilly will acquire the WUSTL-linked neurological disease therapy developer in a $135m deal that could top $1.2bn with milestone payments.

Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.

Nan Fung-backed hearing aid producer Eargo's shares opened at double its IPO price after it floated above its range.